The Early Prediction of Prostate Cancer and Benign Prostate Hyperplasia Additional to Rutin Examination

- , 01.06.2018

Sema Nur Ayyıldız Ali Ayyıldız , Erdal Benli , Selma Cırrık Abdullah Çırakoğlu , Buğra Bilge Keseroğlu

https://doi.org/10.16919/bozoktip.339186

Öz

Aim: To describe new prediction tools in differantion of
Prostate Cancer from BPH during the diagnosis posedüre.

Material
and Methods: BMI was
assessed under three categories: BMI-1 (18.5-24.9 kg/m²), BMI-2
(25.0-29.9 kg/m²), and BMI-3 (30.0 kg/m² or above). New
formations, CRP/NLR, CRP/PSA, NLR/PSA, NLR/BMI, (CRP/PSA)/(age/100),NLR/(PSA/age),NLR/(BMI/age),and(CRP*PSA*age)/100,
developed on the basis of the above four parameters together with age, waist
circumference, neutrophil and lymphocyte counts, were also evaluated. Non-parametric
Mann-Whitney U test and Kruskal-Wallis test were used for Statistical analysis p<0.05
was regarded as significant.

Results: When all pathology results (BPH and PCa) were
considered together with BMI (BMI-1, -2 and -3), waist circumference exhibited
the highest significance in the BPH-BMI-3 (p=0.000) group, NLR in the BPH-BMI-1
(p=0.000) group, and PSA in the PCa-BMI-3 (p=0.000) group. When BMI was
analyzed in the PCa groups, age (mean 71.64+1.32) (p=0.003) and CRP/PSA
(mean 0.42+0.35) (p=0.048) exhibited the highest values in terms of
statistical significance in the BMI-1 group, and PSA (mean 58.85+46.30)
(p=0.020) and waist circumference (mean 82.19+9.66) in the BMI-3 group
(p=0.009)

Conclusions: The combination of PSA, NLR and CRP based on BMI
must be considered before biopsy is performed in the TRUS guideline, which is
still valid for patients with PCa. We think that the new formulations we have
worked to develop can be of clinical use in the event of uncertainly in
differentiating between BPH and PCa. 

Anahtar Kelimeler

Prostate, Cancer, PSA, Neutrophil-Lympocyte Rate, BMI

Kaynakça

• Tanik S, Albayrak S, Zengin K, Borekci H, Bakirtas H, Imamoglu MA et al. Is the neutrophil-lymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia? Asian Pac J Cancer Prev 2014;15:6375-6379.
• Karazanashvili G. Editorial comment on: the relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 2008; 54:1383-1384.
• Ayyıldız SN, Benli E, Çırakoğlu A, Ayyıldız A. Comparison of serum c-reactive protein levels benign prostate hyperplasia and prostate cancer in patients undergoing prostate biopsy. The New Journal of Urology, 2016; 11: 10-15.
• Ayyıldız SN, Ayyıldız A, Benli E, Çırakoğlu A. Erkeklerde alt üriner sistem semptomları ile C-reaktif protein arasında ilişki var mı? Kesitsel bir çalışma. JAREM, 2016; 6: 105-109.
• Ayyıldız SN, Ayyıldız A. PSA, PSA derivatives, ProPSA and prostate health index in the diagnosis of prostate cancer. Turk J Urol 2014; 40: 82-88.
• Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M et al. Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. Eur Urol 2014; 66: 619-622.
• Asgari SA, Mohammadi M. The role of intraprostatic inflammation in the acute urinary retention. Int J Prev Med 2011; 2: 28-31.
• Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143: 747-752.
• Kandirali E, Boran C, Serin E, Semercioz A, Metin A. Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Urology 2007; 70: 743-747.
• Poudel B, Mittal A, Shrestha R, Nepal AK, Shukla PS. Prostate biomarkers with reference to body mass index and duration of prostate cancer. Asian Pac J Cancer Prev 2012; 13: 2149-2152.
• Oh JJ, Jeong SJ, Lee BK, Jeong CW, Byun SS, Hong SK et al. Does obesity affect the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer among men undergoing prostate biopsy. BJU Int 2013; 112: 265-271.
• Tenório TR, Farah BQ, Ritti-Dias RM, Botero JP, Brito DC, Moura PM et al. Relation between leukocyte count, adiposity, and cardiorespiratory fitness in pubertal adolescents. Einstein 2014; 12: 420-424.
• Singer K, Eng DS, Lumeng CN, Gebremariam A, Lee MJ. The relationship between body fat mass percentiles and inflammation in children. Obesity 2014; 22: 1332-1336.
• Aydin M, Yilmaz A, Donma MM, Tulubas F, Demirkol M, Erdogan M et al. Neutrophil/lymphocyte ratio in obese adolescents. North Clin Istanbul 2015; 2: 87-91.
• Bahadır A, Baltacı D, Türker Y, Türker Y, Iliev D, Öztürk S et al. Is the neutrophil-to-lymphocyte ratio indicative of inflammatory state in patients with obesity and metabolic syndrome? Anatol J Cardiol 2015; 15: 816-822.
• Irani J, Levillain P, Goujon JM, Bon D, Doré B, Aubert J. Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol 1997; 157: 1301-1303.
• Kravchick S, Bunkin I, Peled R, Yulish E, Ben-Dor D, Kravchenko Y et al. Patients with elevated serum PSA and indwelling catheter after acute urinary retention: prospective study of 63 patients with 7-year follow-up. J Endourol 2007; 21: 1203-1206.
• Divella R, De Luca R, Abbate I, Naglieri E, Daniele A. Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation. J Cancer 2016; 7: 2346-2359.
• Lauterbach MA, Wunderlich FT. Macrophage function in obesity-induced inflammation and insulin resistance. Pflugers Arch 2017; 469: 385-396.
• Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415-445.
• Rocha VZ, Folco EJ. Inflammatory concepts of obesity. Int J Inflam 2011;2011:529061.
• Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-591.
• Parikesit D, Mochtar CA, Umbas R, Hamid AR. The impact of obesity towards prostate diseases. Prostate Int 2016; 4: 1-6.
• Yelsel K, Alma E, Eken A, Gülüm M, Erçil H, Ayyıldız A. Effect of obesity on international prostate symptom score and prostate volume. Urol Ann 2015; 7: 371-374.
• Toriola AT, Laukkanen JA, Kurl S, Nyyssönen K, Ronkainen K, Kauhanen J. Prediagnostic circulating markers of inflammation and risk of prostate cancer. Int J Cancer 2013; 133: 2961-2967.
• De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011; 60: 106-117.
• Gokce MI, Hamidi N, Suer E, Tangal S, Huseynov A, Ibiş A. Evaluation of neutrophil-to-lymphocyte ratio prior to prostate biopsy to predict biopsy histology: Results of 1836 patients. Can Urol Assoc J 2015; 9: 761-765.
• Kawahara T, Fukui S, Sakamaki K, Ito Y, Ito H, Kobayashi N et al. Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. Oncotarget 2015; 6: 32169-32176.
• Ceylan Y, Günlüsoy B, Degirmenci T, Bolat D, Kozacioglu Z, Vardar E et al. Neutrophil-to-lymphocyte and neutrophil-to-monocyte rates in the decision for a prostate re-biopsy in patients with a previous benign pathology and consistently 2,5-10 ng/ml PSA value. Arch Esp Urol 2016; 69: 627-635.
• Wu VJ, Pang D, Tang WW, Zhang X, Li L, You Z. Obesity, age, ethnicity, and clinical features of prostate cancer patients. Am J Clin Exp Urol 2017; 5: 1-9.
• Chamie K, Oberfoell S, Kwan L, Labo J, Wei JT, Litwin MS. Body mass index and prostate cancer severity: do obese men harbor more aggressive disease on prostate biopsy? Urology 2013; 81: 949-955.
• Donmez I, Mungan A. Prevalance of BPH: national realities. Bull Urooncol 2011; 4: 11-14.
• Benli E, Ayyıdız A. The influence of age on localized prostate cancer: Surgical result of paients over 70 years. Bull Urooncol 2014; 13: 54-57.
• Fujita K, Imamura R, Tanigawa G, Nakagawa M, Hayashi T, Kishimoto N et al. Low serum neutrophil count predicts a positive prostate biopsy. Prostate Cancer Prostatic Dis 2012; 15: 386-390.
• Cihan YB, Arslan A, Ergul MA. Subtypes of white blood cells in patients with prostate cancer or benign prostatic hyperplasia and healthy individuals. Asian Pac J Cancer Prev 2013; 14: 4779-4783.
• Gazel E, Tastemur S, Acikgoz O, Yigman M, Olcucuoglu E, Camtosun A et al. Importance of neutrophil/lymphocyte ratio in prediction of PSA recurrence after radical prostatectomy. Asian Pac J Cancer Prev 2015; 16: 1813-1816.
• Ozer K, Horsanali MO, Gorgel SN, Horsanali BO, Ozbek E. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome. Urol Int 2017; 98: 466-471.